Mazdutide A phase II, randomized, double-blind, placebo-controlled trial showed moderate weight loss with mazdutide in Chinese patients with overweight or obesity without T2DM)
Pharmacogenet Genomics 25:4850, Corrigendum Chen S, Zhou J, Xi M et al (2013) Pharmacogenetic variation and metformin response
Licensed 503A pharmacy partners should prioritize quality standards, transparency, and patient-specific care
8f), and this correlates with our reported increase in mitochondrial mass, ATP production and mTOR activity (Figs
New techniques for improving knowledge about intestinal peptides Despite the advances made in Mutt's laboratory, the isolation and purification of intestinal peptide hormones was time-consuming and expensive